In the original publication, some errors are found and the following corrections should be noted:
In the original publication, some errors are found and the following corrections should be noted:
Section 4, 4th paragraph, 1st sentence, which previously read:
The lower sunitinib hepatic exposure in female mice may anticipate both, the lesser susceptibility to toxicity observed of male patients [32] , and the higher incidence (p = 0.016) of C3 grade adverse events [14, 15] and risk (p = 0.04) of thrombocytopenia [16] in female patients.
Should read:
The lower sunitinib hepatic exposure in male mice may anticipate both, the lesser susceptibility to toxicity observed of male patients [32] , and the higher incidence (p = 0.016) of C3 grade adverse events [14, 15] and risk (p = 0.04) of thrombocytopenia [16] in female patients.
Section 4.1, 1st paragraph, 4th sentence, which previously read:
In fact, 32 % of patients discontinued sunitinib treatment because of a lack of efficacy [35] and this percentage increased to 49 % in the main clinical trial [24] .
In fact, 32 % of patients discontinued sunitinib treatment because of a lack of efficacy [35] and this percentage increased to 39 % in the main clinical trial [24] .
The online version of the original article can be found under doi:10. 1007/s40261-016-0428-5.
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